Allergan plc Sees Unusually High Options Volume (AGN)

Allergan plc (NYSE:AGN) was the recipient of some unusual options trading activity on Friday. Investors acquired 2,693 call options on the company. This is an increase of 318% compared to the typical daily volume of 644 call options.

In other Allergan plc news, Director Paul Bisaro sold 70,000 shares of Allergan plc stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $246.68, for a total transaction of $17,267,600.00. Following the transaction, the director now directly owns 274,226 shares of the company’s stock, valued at $67,646,069.68. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Nesli Basgoz sold 1,889 shares of Allergan plc stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total transaction of $416,430.05. The disclosure for this sale can be found here. Insiders own 0.27% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGN. Crestwood Advisors Group LLC bought a new position in Allergan plc during the first quarter valued at about $103,000. Sunbelt Securities Inc. purchased a new position in Allergan plc during the fourth quarter valued at about $107,000. Feltz Wealth PLAN Inc. purchased a new position in Allergan plc during the first quarter valued at about $107,000. Enterprise Financial Services Corp boosted its position in Allergan plc by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares in the last quarter. Finally, JNBA Financial Advisors boosted its position in Allergan plc by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares in the last quarter. Hedge funds and other institutional investors own 86.40% of the company’s stock.

A number of research analysts have weighed in on AGN shares. Vetr cut shares of Allergan plc from a “buy” rating to a “hold” rating and set a $228.27 price target on the stock. in a research report on Wednesday, February 1st. Leerink Swann set a $271.00 price target on shares of Allergan plc and gave the company a “buy” rating in a research report on Thursday, February 2nd. Mizuho reaffirmed a “buy” rating and set a $275.00 price target (up from $273.00) on shares of Allergan plc in a research report on Tuesday, February 7th. Credit Suisse Group AG reaffirmed a “buy” rating and set a $274.00 price target on shares of Allergan plc in a research report on Tuesday, February 14th. Finally, Royal Bank of Canada set a $279.00 price target on shares of Allergan plc and gave the company a “buy” rating in a research report on Tuesday, February 14th. Six research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Allergan plc presently has a consensus rating of “Buy” and an average target price of $267.21.

Shares of Allergan plc (NYSE:AGN) traded down 0.42% during mid-day trading on Friday, hitting $223.42. 749,217 shares of the company were exchanged. The stock’s 50-day moving average price is $234.61 and its 200 day moving average price is $223.27. Allergan plc has a 12-month low of $184.50 and a 12-month high of $261.27. The stock has a market cap of $75.04 billion, a PE ratio of 6.96 and a beta of 1.07.

Allergan plc (NYSE:AGN) last issued its earnings results on Tuesday, May 9th. The company reported $3.35 EPS for the quarter, beating analysts’ consensus estimates of $3.32 by $0.03. The business had revenue of $3.57 billion during the quarter, compared to analyst estimates of $3.53 billion. Allergan plc had a return on equity of 7.21% and a net margin of 100.04%. Allergan plc’s revenue was up 5.1% on a year-over-year basis. During the same period in the prior year, the company posted $3.04 earnings per share. On average, equities analysts anticipate that Allergan plc will post $16.11 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 15th. Shareholders of record on Thursday, May 18th will be paid a dividend of $0.70 per share. The ex-dividend date of this dividend is Tuesday, May 16th. This represents a $2.80 annualized dividend and a yield of 1.25%.

WARNING: This report was first posted by sleekmoney and is owned by of sleekmoney. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://sleekmoney.com/allergan-plc-sees-unusually-high-options-volume-agn/1856260.html.

About Allergan plc

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

12 Month Chart for NYSE:AGN

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/allergan-plc-sees-unusually-high-options-volume-agn/1856260.html

Receive News & Ratings for Allergan plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan plc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *